Tara Baetz

2.6k citations

71 papers · 1.5k indexed · h-index 20

Impact in

Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Viral-associated cancers and disorders
- HER2/EGFR in Cancer Research
Pathology and Forensic Medicine top 2%
- Lymphoma Diagnosis and Treatment

Papers in ⓘ

Oncology 55
- Cancer Immunotherapy and Biomarkers 23
- CAR-T cell therapy research 19
- Cutaneous Melanoma Detection and Management 10
- Viral-associated cancers and disorders 6
Pathology and Forensic Medicine 25
- Lymphoma Diagnosis and Treatment 25

Co-authors: Adi Kartolo (18 shared papers)Wilma M. Hopman (16 shared papers)Michael Crump (11 shared papers)D. Scott Ernst (4 shared papers)Ralph M. Meyer (8 shared papers)Stephen Couban (6 shared papers)Kevin Imrie (3 shared papers)Elizabeth A. Eisenhauer (7 shared papers)
Journals: Journal of Clinical Oncology (9 papers)Blood (6 papers)Clinical Cancer Research (3 papers)Journal of Immunotherapy (3 papers)Investigational New Drugs (3 papers)
Partner nations: Canada United States Italy

In The Last Decade

Tara Baetz

65 papers receiving 1.4k citations

Peers

Countries citing papers authored by Tara Baetz

Since Specialization

Citations

This map shows the geographic impact of Tara Baetz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tara Baetz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tara Baetz more than expected).

Fields of papers citing papers by Tara Baetz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tara Baetz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tara Baetz. The network helps show where Tara Baetz may publish in the future.

Co-authors

The 25 scholars most cited alongside Tara Baetz, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Tara Baetz Line = papers co-authored together Tara Baetz links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 71 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Randomized Phase II Study of Two Doses of Gefitinib in Hormone-Refractory Prostate Cancer: A Trial of the National Cancer Institute of Canada-Clinical Trials Group Journal of Clinical Oncology ·Christina M. Canil, Malcolm J. Moore, Eric Winquist, Tara Baetz, Michaël Pollak, K.N. Chi, Scott Berry, D. Scott Ernst, L. Douglas, Michael Brundage, B. Fisher, Anne McKenna, Lesley Seymour	2005	169
2	Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20⁺ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study Journal of Clinical Oncology ·Laurie H. Sehn, André Goy, Fritz Offner, Giovanni Martinelli, Marı́a Dolores Caballero, Ole Gadeberg, Tara Baetz, Andrew D. Zelenetz, Gianluca Gaïdano, Luis Fayad, Rena Buckstein, Jonathan W. Friedberg, Michael Crump, Branimir Jakšić, Pier Luigi Zinzani, Swaminathan P. Iyer, Deniz Şahin, Akiko Chai, Günter Fingerle‐Rowson, Oliver W. Press	2015	122
3	Gemcitabine, dexamethasone and cisplatin is an active andnon-toxic chemotherapy regimen in relapsed or refractory Hodgkin’s disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group Annals of Oncology ·Tara Baetz, Andrew R. Belch, Stephen Couban, Kevin Imrie, J. Yau, Robert E. Myers, Keyue Ding, Narinder Paul, L. E. Shepherd, José Iglesias, Ralph M. Meyer, Michael Crump	2003	120
4	Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+-Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC) Clinical Cancer Research ·Stacy L. Moulder, Virginia F. Borges, Tara Baetz, Tessa McSpadden, Gina Fernetich, Rashmi K. Murthy, Renae Chavira, Kari Guthrie, Emma Barrett, Stephen Chia	2017	111
5	Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B‐cell non‐Hodgkin lymphoma Cancer ·Michael Crump, Tara Baetz, Stephen Couban, Andrew R. Belch, Deborah Marcellus, Kang Howson‐Jan, Kevin Imrie, Robert E. Myers, Grenfell Adams, Keyue Ding, Nancy Paul, Lois E. Shepherd, José Iglesias, Ralph M. Meyer	2004	94
6	Phase II Study of Perifosine in Previously Untreated Patients with Metastatic Melanoma Investigational New Drugs ·D. Scott Ernst, Elizabeth A. Eisenhauer, Nancy Wainman, M. L. Davis, Reinhard Lohmann, Tara Baetz, Karl Bélanger, Michael Smylie	2005	89
7	Predictors of Immunotherapy-Induced Immune-Related Adverse Events Current Oncology ·Adi Kartolo, J. Sattar, Varunika Sahai, Tara Baetz, Joshua Lakoff	2018	89
8	The efficacy and toxicity of immune checkpoint inhibitors in a real-world older patient population Journal of Geriatric Oncology ·Joobin Sattar, Adi Kartolo, Wilma M. Hopman, Joshua Lakoff, Tara Baetz	2018	55
9	Inactivation of the CDKN2A Tumor-Suppressor Gene by Deletion or Methylation Is Common at Diagnosis in Follicular Lymphoma and Associated with Poor Clinical Outcome Clinical Cancer Research ·Abdulmohsen Alhejaily, Andrew G. Day, Harriet Feilotter, Tara Baetz, David P. LeBrun	2014	47
10	Primary cardiac diffuse large B cell lymphoma presenting with superior vena cava syndrome Canadian Journal of Cardiology ·Amer M. Johri, Tara Baetz, Phillip A. Isotalo, Robert L. Nolan, Anthony Sanfilippo, Glorianne Ropchan	2009	43
11	Discordance Between Conclusions Stated in the Abstract and Conclusions in the Article: Analysis of Published Randomized Controlled Trials of Systemic Therapy in Lung Cancer Journal of Clinical Oncology ·Abdullah Altwairgi, Christopher M. Booth, Wilma M. Hopman, Tara Baetz	2012	33
12	Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12 Blood ·John Kuruvilla, David MacDonald, C. Tom Kouroukis, Matthew C. Cheung, Harold J. Olney, A. Robert Turner, Peter Anglin, Matthew D. Seftel, Walid Sabry Ismail, Stefano Luminari, Stephen Couban, Tara Baetz, Ralph M. Meyer, Annette E. Hay, Lois E. Shepherd, Marina Djurfeldt, Syed Sameer Aga, Bingshu E. Chen, Michael Crump	2015	28
13	Serum Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Prognosticating Immunotherapy Efficacy Immunotherapy ·Adi Kartolo, Ryan Holstead, Sidra Khalid, Jeffrey Emack, Wilma M. Hopman, Andrew Robinson, Tara Baetz	2020	27
14	A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours Investigational New Drugs ·Tara Baetz, Elizabeth A. Eisenhauer, Lillian L. Siu, Martha MacLean, Karen Doppler, Wendy Walsh, B. Fisher, Azhar Khan, Dinesh P. de Alwis, Aaron Weitzman, Leslie H. Brail, Malcolm Moore	2006	25
15	Gemcitabine/Dexamethasone/Cisplatin vs Cytarabine/Dexamethasone/Cisplatin for Relapsed or Refractory Aggressive-Histology Lymphoma: Cost-Utility Analysis of NCIC CTG LY.12 JNCI Journal of the National Cancer Institute ·Matthew C. Cheung, Annette E. Hay, Michael Crump, Kevin Imrie, Yuyao Song, Shazia Hassan, Nancy Risebrough, Jonathan Sussman, Stephen Couban, David MacDonald, Vishal Kukreti, C. Tom Kouroukis, Tara Baetz, David Szwajcer, P. Desjardins, Lois E. Shepherd, Ralph M. Meyer, Al Le, Bingshu E. Chen, Nicole Mittmann	2015	20
16	Abundant expression of interleukin-21 receptor in follicular lymphoma cells is associated with more aggressive disease Leukemia & lymphoma ·Brianne Wood, Soma Sikdar, Suk Jin Choi, Shakeel Virk, Abdulmohsen Alhejaily, Tara Baetz, David P. LeBrun	2012	20
17	Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients Current Oncology ·Justin Tong, Adi Kartolo, Cynthia Yeung, Wilma M. Hopman, Tara Baetz	2022	20
18	Safety of Immunotherapy Rechallenge After Immune-related Adverse Events in Patients With Advanced Cancer Journal of Immunotherapy ·Adi Kartolo, Ryan Holstead, Sidra Khalid, Jeffrey Emack, Wilma M. Hopman, Tara Baetz	2020	20
19	Safety and Clinical Outcomes of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Diseases Journal of Immunotherapy ·Cynthia Yeung, Adi Kartolo, Ryan Holstead, Gordon Taylor Moffat, Lilian Hanna, Wilma Hopman, Joshua Lakoff, Tara Baetz	2021	19
20	[¹⁸F]‐FDG PET/CT in the staging and management of indolent lymphoma: A prospective multicenter PET registry study Cancer ·Ur Metser, Jill Dudebout, Tara Baetz, David Hodgson, Deanna L. Langer, Pamela MacCrostie, Victor Mak, Noam Tau	2017	19

About Tara Baetz

Tara Baetz is a scholar working on Oncology, Pathology and Forensic Medicine, Molecular Biology, Pulmonary and Respiratory Medicine and Immunology, having authored 71 papers that have together received 1.5k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (25 papers), Cancer Immunotherapy and Biomarkers (23 papers), CAR-T cell therapy research (19 papers), Melanoma and MAPK Pathways (13 papers), Cutaneous Melanoma Detection and Management (10 papers), Chronic Lymphocytic Leukemia Research (8 papers), Viral-associated cancers and disorders (6 papers) and Immunotherapy and Immune Responses (6 papers). The work is most often cited by research in Oncology (904 citations), Pathology and Forensic Medicine (514 citations), Genetics (261 citations), Pulmonary and Respiratory Medicine (391 citations) and Neurology (155 citations). Tara Baetz has collaborated with scholars based in Canada, United States and Italy. Frequent co-authors include Adi Kartolo, Wilma M. Hopman, Michael Crump, D. Scott Ernst, Ralph M. Meyer, Stephen Couban, Kevin Imrie, Elizabeth A. Eisenhauer, Andrew R. Belch and José Iglesias. Their work appears in journals such as Journal of Clinical Oncology, Blood, Clinical Cancer Research, Journal of Immunotherapy and Investigational New Drugs.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact